Trial · NCT01903005
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Retention in Treatment in the Safety Population | Treatment retention was assessed at weeks 4, 8, 12, 16, 20, and 24 | Safety population | participants | NUMBER |
| SECONDARY | Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Clinical Opioid Withdrawal Scale (COWS) Score | Prior to dosing on day 1, at weeks 4, 8,12,16, 20, 24, and at study endpoint | Safety population; patient population at day 1 (n=658) is lower than overall safety population (n=665) due to missing data | units on a scale | MEAN |
| SECONDARY | Mean Change From Primary Study Baseline (OX219-006 or OX219-007) in Subjective Opioid Withdrawal Scale (SOWS) Score | Prior to dosing on day 1, at weeks 4, 8,12,16, 20, and 24, and at study endpoint | Safety population; patient population at day 1 (n=650) is lower than overall safety population (n=665) due to missing data | units on a scale | MEAN |
| SECONDARY | Mean Change From Primary Study Baseline (OX219-006 and OX219-007) in Visual Analog Scale (VAS) Craving Scores | Prior to dosing on day 1, at weeks 4, 8, 12, 16, 20, and 24, and at study endpoint | Safety population; patient population at day 1 (n=646) is lower than overall safety population (n=665) due to missing data | units on a scale | MEAN |
| SECONDARY | Percent Change From Primary Study Baseline (OX219-006 or OX219-007) for Question 1 of the Work Productivity/Activity Impairment: 6-Question Specific Health Problem Questionnaire (WPAI:SHP) | Study Endpoint | Safety population; patients with missing data were excluded from the analysis and are reflected in the number of patients analyzed | percentage of patients | NUMBER |
| SECONDARY | Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 2-4 of the WPAI:SHP | Week 24 | Safety population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed | hours | MEAN |
| SECONDARY | Mean Change From Primary Study Baseline (OX219-006 or OX219-007) for Questions 5-6 of the WPAI:SHP | Week 24 | Safety population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed | units on a scale | MEAN |
| PRIMARY | Number of Patients Reporting Treatment-Emergent Adverse Events | Day 1 through week 24 | Safety population | participants | NUMBER |
| PRIMARY | Number of Patients Reporting Treatment-Related, Treatment-Emergent Adverse Events | Day 1 through week 24 | Safety population | participants | NUMBER |
| PRIMARY | Number of Patients Reporting Treatment-Emergent Serious Adverse Events | Day 1 throught week 24 | Safety population | participants | NUMBER |
| PRIMARY | Number of Patient Discontinuations Due to Treatment-Emergent Adverse Events | Day 1 through week 24 | Safety population | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01903005/outcomes